Expression and purification of soluble single-chain Fv against human fibroblast growth factor receptor 3 fused with Sumo tag in *Escherichia coli*

Zixuan Liu a,1, Jizhou Zhang a,1, Hongqiong Fan,1 Ruofeng Yin,2 Zhong Zheng a, Qian Xu a, Qing Liu a, Haiting He a, Xiaofan Peng a, XinXin Wang a, Xiaokun Li a, Yechen Xiao a,⁎

* a Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Jilin University, Changchun 130021, China
1 b Department of Haematology and Oncology, First Hospital of Jilin University, Changchun 130021, China
2 c Department of Orthopaedic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130031, China
3 d School of Clinical Medicine, Jilin University, Changchun 130021, China

Abstract

Background: Overexpression or mutated activation of Fibroblast growth factor receptor 3 (FGFR3) is involved in the pathogenesis of many tumors. More and more studies focus on the potential usage of therapeutic antibodies against FGFR3.

Results: In this study, a novel single-chain Fv (ScFv) against FGFR3 was prepared and characterized. To achieve the soluble expression, ScFv was fused with Sumo (Small ubiquitin-related modifier) by polymerase chain reaction (PCR), and cloned into pET-20b. The recombinant bacteria were induced by 0.5 mM Isopropyl-β-D-thiogalactopyranoside (IPTG) for 16 h at 20°C, and the supernatant liquid of Sumo-ScFv was harvested and purified by Ni-NTA chromatography. After being cleaved by the Sumo protease, the recombinant ScFv was released from the fusion protein, and further purified by Ni-NTA chromatography. The purity of ScFv was shown to be higher than 95% and their yield reached 4 mg per liter of bacterial culture. In vitro data showed that ScFv can significantly attenuate FGFR3-induced phosphorylation of FGFR3.

Conclusion: We provide a novel method to produce soluble expression and bioactive functions of ScFv in *Escherichia coli*.

© 2015 Pontificia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. All rights reserved.

1. Introduction

Fibroblast growth factors (FGFs), a family of more than 20 known members, play important roles in regulating cell proliferation, differentiation and survival during embryo development and adult stage [1]. FGF receptor (FGFR) mediated FGF-induced signaling pathway. As one of FGFRs, FGFR3 was involved in many diseases, especially cancer. Deregulation of FGFR3 was highlighted and deregulation in many types of cancer, such as multiple myeloma (MM) [2], hepatocellular carcinoma [3] and bladder cancer [4]. Enhancing FGFR3 signaling promotes tumor growth, metastasis and resistance to drug. Thus, FGFR3 has been considered as a novel therapy target for several tumors, such as multiple myeloma [5] and bladder cancer [5,6].

Antibody is considered as one of the most effective strategies against tumor antigens. The single chain Fv (ScFv), containing a variable heavy chain (VH) and a variable light chain (VL) from monoclonal antibody had been considered as a novel therapeutic antibody, and used to kill tumors in recent years, such as anti-Her2 ScFv [7], anti-VEGF ScFv [8] and anti-CAT125 ScFv against epithelial ovarian cancer [9].

In recent ten years, many monoclonal antibodies or ScFvs against FGFR3 have been reported on their anti-tumor activity in vitro and in vivo. One kind of monoclonal antibody against FGFR3 inhibits phosphorylation of FGFR3 and downstream signaling ERK activation in MM cells [10]. ScFv against FGFR3 was shown to block the binding of FGF9 and FGFR3, and inhibits proliferation of bladder cancer cell line RT112 in vitro in a dose- and FGF-dependent manner [11]. Immunotoxin (ScFv-fused toxin) against FGFR3 was reported to inhibit proliferation of bladder cancer cell line RT112 in vitro and exhibited significantly anti-tumor activity in RT112 tumor xenografts by inducing cell apoptosis [12].

The *Escherichia coli* expression system is the principle choice to get recombinant ScFv, however, recombinant ScFv often forms inclusion body using traditional *E. coli* expression method [13,14]. To overcome these shortcomings, we chose a novel expression system, small ubiquitin-related modifier (Sumo) molecular partner. Sumo covalently attached to other proteins to play roles of post-translational modifications [15], including significantly increasing...
the yield of recombinant protein, correctly facilitating target protein folding, and promoting protein solubility [16,17], so Sumo has become an effective biotechnological tool as a fusion system in E. coli, by which many recombinant proteins, such as FGF21 [18], pramlintide [19], ScFv-9R [20], acquired better expression.

In the present study, we construct expression plasmid containing Sumo and ScFv against FGFR3. The recombinant expression plasmid was induced by IPTG in E. coli and purified by Ni-NTA. Further, ScFv was released from Sumo-ScFv cleaved by Sumo enzyme. Our results showed that Sumo is very helpful for promoting the soluble expression of ScFv in E. coli, and the resulting recombinant bioactive ScFv can be used for therapeutic applications and clinical diagnosis of patients in the future.

2. Materials and methods

2.1. Reagents, enzymes, antibodies, bacterial strains

Prime STAR®GXL DNA Polymerase was purchased from TaKaRa Company (Japan). Restriction enzymes NdeI and XhoI were provided by NEB (England). Ni-NTA agarose was purchased from GE healthcare (Sweden). Anti-His tag antibody was provided from Proteintech (Chicago). p–FGFR3 (Tyr724) antibody was purchased from Santa Cruz (USA). Anti-FGFR3 antibody was obtained from Abcam (USA). Anti-beta-actin antibody was purchased from Cell Signaling (USA). E. coli DH5α and E. coli BL21 (DE3) strains were obtained from Invitrogen (USA). The E. coli expression plasmid pET-20b-Sumo containing Sumo fragment was kept in Biochemistry lab, College of Basic Medical Science, Jilin University. Dr. Qi Xiang from Jinan University generously supplied us with the Sumo protease.

2.2. Design of fusion genes and constructions of pET-Sumo-ScFv

The ScFv gene was constructed in a VH-linker-VL format according to the prior report [19] and US patent (8101721B2), and synthesized by ZoonBio Biotechnology Co (China). The primers used for the construction of fusion gene containing ScFv and Sumo fragment were designed as follows: P1 (GGAATTCCATA TGCATCATCATCATCA TCACG) was designed according to the 5′ terminal sequence of Sumo fragment; P2 (5′CTCTGCTGCAGCTGCACCTGACC AATCTGTT CTCTGT3′) contained 3′ terminal sequence of Sumo and 5′ terminal sequence of ScFv. P3 (CCGCTCGAGTTACTGGCCCAGCACGGTCAGT) primer was designed according to the 3′ terminal sequence of ScFv. P3 (CCGCTCGAGTTACTGGCCCAGCACGGTCAGT) primer was designed according to the 3′ terminal sequence of ScFv. As shown in Fig. 1a, Sumo-linker was created by PCR using P1 and P2 as forward and reverse primers, using pET-20b-Sumo as a template. PCR parameters consisted of 5 min of Prime STAR®GXL DNA Polymerase activation at 98°C, followed by 30 cycles of denaturation at 98°C for 10 s, annealing at 60°C for 15 s, extension at 68°C for 30 s, and then a final single extension at 68°C for 5 min.

Further, the Sumo-ScFv was generated by PCR, using P1 and P3 as the forward and reverse primers, using pET-20b-Sumo as a template. The fusion gene was digested with NdeI and XhoI, and inserted into the pET-20b. Finally, the identified recombinant plasmid was confirmed by DNA sequencing (Sangon, Shanghai).

![Fig. 1. Design and synthesis of Sumo-ScFv by PCR. (a) Sumo-ScFv was designed according to the schematic illustration. Firstly, Sumo-linker was created by PCR using P1 and P2. Secondly, Sumo-ScFv was then synthesized by PCR using Sumo-linker and ScFv as templates, P1 and P3 as primers. The final PCR product of Sumo-ScFv was shown in panel (b) and its molecular weight is about 1070 bp.](image)

![Fig. 2. The inducible expression of recombinant Sumo-ScFv and soluble analysis by SDS-PAGE. Bacterial cells containing Sumo-ScFv were induced by 0.5 mM IPTG for 16 h induction at 20°C, then the cell pellets were collected by centrifugation and protein was extracted by sonication and centrifugation. Both soluble and insoluble fractions were analyzed by 12% SDS-PAGE. Compared with negative control (NC) and without IPTG group, Sumo-ScFv highly expressed in recombinant bacteria by IPTG induction (panel (a)). The panel (b) showed total bacteria, supernatant and precipitation of bacterial containing Sumo-ScFv.](image)
2.3. Expression and soluble detection of recombinant Sumo-ScFv

A single colony from *E. coli* BL21 (DE3) harboring pET-Sumo-ScFv was grown overnight in the LB medium (1% peptone, 1% yeast extract and 0.5% sodium chloride, pH 7.0) and incubated in a shaker at 37°C. A 3 ml aliquot of resulting culture was inoculated into 300 ml fresh LB medium and incubated at 37°C and 220 rpm until OD600 was 0.6 to 0.8. Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to 0.5 mM final concentration for 16 h induction at 20°C. The cell pellets were collected by centrifugation and lysed by sonication. The supernatants were harvested by centrifugation at 12,000 × g for 30 min at 4°C, and the remaining pellets (insoluble fraction) containing inclusion bodies were resuspended into an equal volume of lysis buffer. Both soluble and insoluble fractions were analyzed by 12% SDS-PAGE [18].

2.4. Purification of Sumo-ScFv

The cell lysate of Sumo-ScFv was purified by Ni-NTA chromatography. The Ni-NTA resin was washed with wash buffer I (20 mM Tris-HCl, pH 8.0) until OD280 of effluent reached base line. The proteins without 6His-tag were eluted from the column with wash buffer II (20 mM Tris-HCl containing 20 mM imidazole, pH 8.0). Finally, 6His-tagged Sumo-ScFv protein was harvested from the column with elution buffer (20 mM Tris–HCl containing 200 mM imidazole, pH 8.0). The purity of Sumo-ScFv was assessed by SDS-PAGE and its concentration was determined with BCA Protein Assay Kit.

2.5. Cleavage of Sumo from Sumo-ScFv and further purification

The Sumo-ScFv protein was diluted to a concentration of 1 mg ml⁻¹. 10U Sumo protease were added to the dilution in salt buffer (20 mM Tris–HCl, pH 7.0), and the mixture was incubated overnight at 4°C, then the cleaved sample was applied to a Ni-NTA resin column. The recombinant ScFv without His tag was washed directly, but Sumo and Sumo protease containing His-tag were bound to the Ni-NTA resin column. Finally, the recombinant ScFv was desalted overnight with dialysis bag at 4°C.

2.6. Western blot analysis

The immunogenic activity of purified Sumo-ScFv was assayed by Western blot. Total cellular protein was boiled in an equal volume of sample loading buffer, a Tris–HCl buffer (pH 6.8) containing 20% glycerol, 2.5% SDS, 10% β-mercaptoethanol and 0.005% bromophenol blue. Protein samples were electrophoresed on 12% of SDS-PAGE, and then electrophoretically transferred onto PVDF membrane. The nonspecific binding of transferred membrane was blocked with 5% non-fat milk powder overnight. The membrane was incubated with a polyclonal anti-His tag antibody (1:1000), then washed and incubated with a 1:1000 dilution of secondary HRP-conjugated antibody. Immunoreactive bands were visualized using an ECL kit.

2.7. Mass spectrometry analysis

The specific band of ScFv from the SDS-PAGE gel was pooled and analyzed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). This technical service was supported by Beijing Protein Institute Co. Ltd.

2.8. Inhibition of FGFR3 signaling by ScFv in RT112 cells

RT112 cells were grown overnight in DMEM medium containing 10% FBS, 100 U ml⁻¹ ampicillin and 100 U ml⁻¹ streptomycin at 37°C of cell incubator. Before stimulation, cells were firstly starved with DMEM medium without FBS in the absence or presence of ScFv for 14 h, and then stimulated with 10 ng ml⁻¹ FGF9 for 30 min. Then total...
was in conformity with the expected sequence. The sequence of fusion gene can be found in GenBank (accession number KP405837).

### 3.2. Expression and purification of Sumo-ScFv

_E. coli_ cells harboring Sumo-ScFv were induced by 0.5 mM IPTG for 16 h at 20°C, then the cell pellets were harvested by centrifugation and protein was extracted and separated by sonication and centrifugation. The supernatants and precipitate were collected and performed to 12% SDS-PAGE analysis. As shown in Fig. 2a, the expression of a 39 kDa protein which is similar to the predicted size was induced by IPTG, compared with negative control (blank plasmid) or recombinant bacteria without IPTG induction.

To detect the soluble expression of recombinant Sumo-ScFv, the supernatant and precipitate of cell lysate were both analyzed by SDS-PAGE and the results showed Sumo-ScFv highly expressed in the fraction of both supernatant and precipitate, but soluble fractions (supernatant) exceed 50% of total target protein. Previous studies showed that recombinant ScFv often forms inclusion body using traditional _E. coli_ expression method [13,14]. Our results suggested that Sumo may be very helpful to promote soluble expression of recombinant ScFv.

To acquire high purity recombinant protein, Ni-NTA was applied to the Ni-NTA column. Only ScFv was separated from ScFv by Ni-NTA column. SDS-PAGE analysis showed a 26 kDa band of ScFv, and its purity exceeds 95%. Since the 6His-tag and start codon were put in the N-terminal of Sumo-ScFv, the recombinant Sumo-ScFv was efficiently eluted from the column when washed off the resin with elution buffer. Because ScFv has no His tag, Sumo fragment from Sumo-ScFv could be separated from ScFv by Ni-NTA column. SDS-PAGE analysis showed a 26 kDa band of ScFv, and its purity exceeds 95%. Since the 6His-tag and start codon were put in the N-terminal of Sumo-ScFv, the recombinant ScFv has a natural amino acid sequence without any tags after cleavage of Sumo. This showed that Sumo expression system is a feasible method to acquire natural recombinant protein without any tags.

### 3.3. Further purification and determination of ScFv after cleavage of Sumo

To cleave Sumo fragment from the fusion protein, the purified Sumo-ScFv was digested by Sumo protease for 10 h at 4°C, and then applied to the Ni-NTA column. The Sumo and Sumo protease containing 6His-tag were affiliated by Ni-NTA resin, only ScFv was eluted from the column when washed off the resin with elution buffer. As shown in Fig. 4, SDS-PAGE analysis showed that more than 90% recombinant Sumo-ScFv was efficiently cleaved by Sumo protease. The immunoactivity of ScFv could not be performed because there are no specific antibodies or antigens against recombinant ScFv. To confirm the authenticity of ScFv, ScFv was successfully identified by Mass spectrometric method and detailed data was shown in Fig. 5b. The results indicated that the data of score and sequence coverage both match the amino acid sequence of ScFv.

### 3.4. Identification of recombinant Sumo-ScFv and ScFv

To assay the authenticity of fusion protein, the immunoactivity of purified Sumo-ScFv was performed with anti-his tag antibody by Western blot due to 6His-tag designed in the N-terminal of Sumo. The results revealed that Sumo-ScFv (Fig. 5a, lane 1 and lane 2) could specifically react with anti-his tag antibody.

The immunoactivity of ScFv could not be performed because there are no specific antibodies or antigens against recombinant ScFv. To confirm the authenticity of ScFv, ScFv was successfully identified by Mass spectrometric method and detailed data was shown in Fig. 5b. The results indicated that the data of score and sequence coverage both match the amino acid sequence of ScFv.

### 3.5. ScFv specifically inhibits FGFR3 signaling in RT112 cells

To investigate whether ScFv has bioactivity against FGFR3 positive cells, the bladder cancer RT112 cells which highly expressed FGFR3 were stimulated by FGF9 in the absence or presence of ScFv. The phosphorylation of FGFR3 which represents receptor kinase activity was detected by Western blot with specific antibody against p-FGFR3 and FGFR3. The immunoactivity of ScFv could not be performed because there are no specific antibodies or antigens against recombinant ScFv. To confirm the authenticity of ScFv, ScFv was successfully identified by Mass spectrometric method and detailed data was shown in Fig. 5b. The results indicated that the data of score and sequence coverage both match the amino acid sequence of ScFv.

To cleave Sumo fragment from the fusion protein, the purified Sumo-ScFv was digested by Sumo protease for 10 h at 4°C, and then applied to the Ni-NTA column. The Sumo and Sumo protease containing 6His-tag were affiliated by Ni-NTA resin, only ScFv was eluted from the column when washed off the resin with elution buffer. As shown in Fig. 4, SDS-PAGE analysis showed that more than 90% recombinant Sumo-ScFv was efficiently cleaved by Sumo protease.

To cleave Sumo fragment from the fusion protein, the purified Sumo-ScFv was digested by Sumo protease for 10 h at 4°C, and then applied to the Ni-NTA column. The Sumo and Sumo protease containing 6His-tag were affiliated by Ni-NTA resin, only ScFv was eluted from the column when washed off the resin with elution buffer. As shown in Fig. 4, SDS-PAGE analysis showed that more than 90% recombinant Sumo-ScFv was efficiently cleaved by Sumo protease. Because ScFv has no His tag, Sumo fragment from Sumo-ScFv could be separated from ScFv by Ni-NTA column. SDS-PAGE analysis showed a 26 kDa band of ScFv, and its purity exceeds 95%. Since the 6His-tag and start codon were put in the N-terminal of Sumo-ScFv, the recombinant ScFv has a natural amino acid sequence without any tags after cleavage of Sumo. This showed that Sumo expression system is a feasible method to acquire natural recombinant protein without any tags.
and had competition activity with FGFR9 by blocking FGFR3 activation and inhibited RT112 cell proliferation. Next, we also deeply study ScFv functions in blocking proliferation, migration and invasion of FGFR3 positive cancer cells. In recent years, tumor-specific immunoliposome has become a novel delivery tool to carry siRNA drug or chemical drug [21]. It’s possible that our ScFv will be used to make immunoliposome for tumor target therapy.

4. Conclusions

In this study, we report that the expression, purification and characterization of a novel ScFv antibody against FGFR3. This procedure which fused with Sumo tag promotes the soluble expression of recombinant ScFv and acquires natural and bioactive protein.

Conflict of interests

We declare that there is no conflict of interest regarding the publication of this work.

Financial support

This work was supported by the Key Science & Technology Funding of Jilin Province (20130206003YY), Bio-pharmaceutical grant from Jilin Provincial Science & Technology Department (20130727041YY) and National Natural Science Foundation of China (No. 81370640).

References

[1] Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437:199–213. http://dx.doi.org/10.1042/bjo20101603.
[2] Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000;95:992-8.
[3] Qiu WH, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 2005;11:5266–72.
[4] Di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: Past, present, and future challenges. Adv Urol 2012;2012:429213. http://dx.doi.org/10.1155/2012/429213.
[5] Qiao J, Du X, Chen Y, Chan P, Li H, Wu P. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009;119:1216–29. http://dx.doi.org/10.1172/JCI38017.
[6] Du X, Wang QR, Chan E, Merchant M, Liu J, French D, et al. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res 2012;72:5843-55. http://dx.doi.org/10.1158/0008-5472.can-12-1329.
[7] Akbani V, Mir Mohammad Sadeghi H, Jafrihan-Dekordi A, Abedi D, Chou CP. Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. J Ind Microbiol Biotechnol 2014;41:947–56. http://dx.doi.org/10.1007/s10295-014-1437-0.
[8] Hosseini H, Rajabiaz M, Ebrahimizadeh W, Dehbid CR. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF. Microvasc Res 2015;97:13–8. http://dx.doi.org/10.1016/j.mvr.2014.09.002.
[9] Sharma SK, Suresh MR, Wuest FR. Improved soluble expression of a single-chain antibody fragment in E. coli for targeting CA125 in epithelial ovarian carcinoma. Protein Expr Purif 2014;102:27–37. http://dx.doi.org/10.1016/j.pep.2014.07.007.
[10] Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107:4039–46. http://dx.doi.org/10.1182/blood-2005-10-1479.
[11] Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, Saenz P, Martínez A, Casal JL. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005;11:6280–90. http://dx.doi.org/10.1158/1078-0432.cs-05-0282.
[12] Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, Barceras R, Cañamero M, Ferreiro S, et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 2008;7:862–73. http://dx.doi.org/10.1158/1535-7163.mct-07-0394.
[13] Bu D, Zhou Y, Tang J, Jing F, Zhang W. Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli. Protein Expr Purif 2013;92:203–7. http://dx.doi.org/10.1016/j.pep.2013.10.002.
[14] Yuasa N, Koyama T, Fujita-Yamaguchi Y. Purification and refolding of anti-T-antigen single chain antibodies (scFvS) expressed in Escherichia coli as inclusion bodies. Biose Technol 2008;4:24–31. http://dx.doi.org/10.5582/bst.8.24.
[15] Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004;73:355–82. http://dx.doi.org/10.1146/annurev.biochem.73.012903.104758.
[16] Butt TR, Edavettal SC, Hall JP, Mattern MR. SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif 2005;43:1–9. http://dx.doi.org/10.1016/j.pep.2005.03.016.
[17] Huang Y, Su Z, Li Y, Zhang Q, Cui L, Su Y, et al. Expression and purification of glutathione transferase-small ubiquitin-related modifier-metallothionein fusion protein and its neuronal and hepatic protection against D-galactose-induced oxidative damage in mouse model. J Pharmacol Exp Ther 2009;329:469–78. http://dx.doi.org/10.1124/jpet.108.149401.
[18] Wang H, Xiao Y, Fu L, Zhao H, Zhang Y, Wan X, et al. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol 2010;10:14. http://dx.doi.org/10.1186/1472-6750-10-14.
[19] Hu H, Xiang Q, Liu H, Qu H, Tang X, Xiao X, et al. Expression, purification, and biological activity of the recombinant pramlintide precursor. Appl Microbiol Biotechnol 2014;98:7837–44. http://dx.doi.org/10.1007/s00253-014-5699-2.
[20] Zhou Y, Wang S, Zhang H, Bao J, Zhang C, Li H, et al. High-level expression, purification, and characterization of bifunctional ScFv-9R fusion protein. Appl Microbiol Biotechnol 2014;98:5499–506. http://dx.doi.org/10.1007/s00253-014-5541-x.
[21] Gao J, Yu Y, Zhang Y, Song J, Chen H, Li W, et al. EGRF-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials 2012;33:270–82. http://dx.doi.org/10.1016/j.biomaterials.2011.09.035.